Elite Clinical Trials Studies Major Depressive Disorder Drug

Elite Clinical Trials is testing the effectiveness of antidepressants in children and adolescents suffering from Major Depressive Disorder.

Both males and females ranging from 12 to 17 years of age are welcome to participate in the study if qualified. 

Elite Clinical Trials' staff of experienced doctors will research the effectiveness of Desvenlaxfine (Pristiq) in comparison to Fluoxetine (Prozac).

Elite Clinical Trials researches and tests some of the most cutting edge medications being introduced to the medical world.

This study will determine whether Pristiq sustained release with a placebo is effective in treating children and adolescents with Major Depressive Disorder.

The study will use an active control, meaning it will compare the effects of the study drug, Pristiq, to a drug already known to work for the condition being researched.

In this particular study, the antidepressant more commonly known as Prozac will be used as the active control, which has been proven to effectively treat children and adolescents suffering from Major Depressive Disorder.

Neither the administrative doctor or the patient will know which medication they are receiving for the study, making it a double blind study.

The Major Depressive Disorder study will be 17 weeks long and will require 10 visits to the office for various physical examinations and labs. Electrocardiograms to check the electrical activity in a patient's heart will be conducted as well.

As always, Elite Clinical Trials will be compensating participating patients for their time and travel.

Any proper doses of drugs used in the study will also be given to participants free of charge. 

The Major Depressive Disorder study will be conducted in multiple Elite Clinical Trials centers.

To find a clinical trial in your area by contacting Elite Clinical Trials at (951) 678-1551
Visit Elite Clinical Trials at:
34859 Fredrick St. Suite 110
Wildomar, Ca 92595







0 Comments:

Post a Comment

Menifee 24/7 welcomes comments from readers in response to posts on our website and on our Facebook page. Comments on our website must be submitted through a Google account with the user's full name. No anonymous comments are allowed. On both the website and our Facebook page, use of profanity, personal attacks, statement as fact of things that have not been substantiated, or statements of a generally offensive tone are prohibited.

Loading